Part 1 – Case Presentation
Brian A. Jonas, MD, PhD, FACP, presents the case of patient “C.O.” to fellow faculty members Daniel A. Pollyea, MD, MS, and Gabriel N. Mannis, MD. The virtual roundtable panel discusses unique features of the case and explores hypothetical variations of the circumstances, as well as offering insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).
Click here to learn more by viewing Part 2 – Case Discussion.
Disclosures: Brian A. Jonas, MD, PhD, FACP Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC Travel Reimbursement: AbbVie Gabriel N. Mannis, MD Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz Daniel A. Pollyea, MD, MS Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas References:
- Ghandili et al. Blood Advances. 2020;4(23):5936-5941.
- https://www.nccn.org/covid-19/pdf/COVID-19_Vaccination_Guidance_V1.0.pdf
- https://www.cdc.gov/coronavirus/2019-ncov/index.html
- https://www.hematology.org/covid-19
- https://www.asco.org/asco-coronavirus-information
